B_s ---> \gamma \gamma decay in the model III and 3HDM(O_2) with CP violating effects

We analyse the CP asymmetry for B_{s} -->\gamma\gamma in the two Higgs doublet model with tree level flavor changing currents (model III) and three Higgs doublet model with O_2 symmetry in the Higgs sector, including O_{7} type long distance effects. Further, we study the dependencies of the branching ratio Br(B_{s} --> \gamma\gamma)$ and the ratio of CP-even and CP-odd amplitude squares, R=|A^{+}|^2/|A^{-}|^2, on the CP parameter sin \theta. We found that, there is a weak CP asymmetry, at the order of 10^{-4}. Besides, the branching ratio Br(B_{s} --> \gamma\gamma), and also R ratio, is not sensitive to the CP parameter for |\frac{\bar{\xi}^{U}_{N,tt}}{\bar{\xi}^{D}_{N,bb}}|<1.Comment: 17 pages, 11 figure

On the Nonabelian Aharonov Bohm Scattering of Spinless Particles

The Aharonov Bohm scattering for spinless, isospin 1/2, particles interacting through a nonabelian Chern-Simons field is studied. Starting from the relativistic quantum field theory and using a Coulomb gauge formulation, the one loop renormalization program is implemented. Through the introduction of an intermediary cutoff, separating the regions of high and low integration momentum, the nonrelativistic limit is derived. The next to leading relativistic approximation is also determined. In this approach quantum field theory vacuum polarization effects are automatically incorporated.Comment: 20 pages, 8 figures, revtex. Misspelled reference corrected and new references adde

Neutral Higgs bosons in the MNMSSM with explicit CP violation

Within the framework of the minimal non-minimal supersymmetric standard model (MNMSSM) with tadpole terms, CP violation effects in the Higgs sector are investigated at the one-loop level, where the radiative corrections from the loops of the quark and squarks of the third generation are taken into account. Assuming that the squark masses are not degenerate, the radiative corrections due to the stop and sbottom quarks give rise to CP phases, which trigger the CP violation explicitly in the Higgs sector of the MNMSSM. The masses, the branching ratios for dominant decay channels, and the total decay widths of the five neutral Higgs bosons in the MNMSSM are calculated in the presence of the explicit CP violation. The dependence of these quantities on the CP phases is quite recognizable, for given parameter values.Comment: 25 pages, 8 figure

The Rare Decay D^0 -> gamma gamma

We present a calculation of the rare decay mode D^0 -> gamma gamma, in which the long distance contributions are expected to be dominant. Using the Heavy Quark Chiral Perturbation Theory Lagrangian with a strong g coupling as recently determined by CLEO from the D^* -> D pi width, we consider both the anomaly contribution which relates to the annihilation part of the weak Lagrangian and the one-loop pi, K diagrams. The loop contributions which are proportional to g and contain the a_1 Wilson coefficient are found to dominate the decay amplitude, which turns out to be mainly parity violating. The branching ratio is then calculated to be (1.0+-0.5)x10^(-8). Observation of an order of magnitude larger branching ratio could be indicative of new physics.Comment: 16 pages, 5 figures, additional reference and several remarks added, results unchange

Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

Background and Objectives: Research in Multiple Sclerosis (MS) has recently focused on extracting knowledge from real-world clinical data sources. This type of data is more abundant than data produced during clinical trials and potentially more informative about real-world clinical practice. However, this comes at the cost of less curated and controlled data sets. In this work we aim to predict disability progression by optimally extracting information from longitudinal patient data in the real-world setting, with a special focus on the sporadic sampling problem. Methods: We use machine learning methods suited for patient trajectories modeling, such as recurrent neural networks and tensor factorization. A subset of 6682 patients from the MSBase registry is used. Results: We can predict disability progression of patients in a two-year horizon with an ROC-AUC of 0.85, which represents a 32% decrease in the ranking pair error (1-AUC) compared to reference methods using static clinical features. Conclusions: Compared to the models available in the literature, this work uses the most complete patient history for MS disease progression prediction and represents a step forward towards AI-assisted precision medicine in MS

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

To compare treatment persistence between two dosages of interferon &beta;-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics. Treatment discontinuations were evaluated in all patients within the MSBase registry who commenced interferon &beta;-1a SC thrice weekly (n = 4678). Furthermore, we assessed 2-year clinical outcomes in 1220 patients treated with interferon &beta;-1a in either dosage (22 &micro;g or 44 &micro;g) as their first disease modifying agent, matched on propensity score calculated from pre-treatment demographic and clinical variables. A subgroup analysis was performed on 456 matched patients who also had baseline MRI variables recorded. Overall, 4054 treatment discontinuations were recorded in 3059 patients. The patients receiving the lower interferon dosage were more likely to discontinue treatment than those with the higher dosage (25% vs. 20% annual probability of discontinuation, respectively). This was seen in discontinuations with reasons recorded as &ldquo;lack of efficacy&rdquo; (3.3% vs. 1.7%), &ldquo;scheduled stop&rdquo; (2.2% vs. 1.3%) or without the reason recorded (16.7% vs. 13.3% annual discontinuation rate, 22 &micro;g vs. 44 &micro;g dosage, respectively). Propensity score was determined by treating centre and disability (score without MRI parameters) or centre, sex and number of contrast-enhancing lesions (score including MRI parameters). No differences in clinical outcomes at two years (relapse rate, time relapse-free and disability) were observed between the matched patients treated with either of the interferon dosages. Treatment discontinuations were more common in interferon &beta;-1a 22 &micro;g SC thrice weekly. However, 2-year clinical outcomes did not differ between patients receiving the different dosages, thus replicating in a registry dataset derived from &ldquo;real-world&rdquo; database the results of the pivotal randomised trial. Propensity score matching effectively minimised baseline covariate imbalance between two directly compared sub-populations from a large observational registry